Molecular Profiling of Lymphatic Endothelial Cell Activation In Vitro.
RNA sequencing
lymphangiogenesis
lymphatic activation
lymphatic endothelial cells
molecular profile
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
26
10
2023
revised:
18
11
2023
accepted:
20
11
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
9
12
2023
Statut:
epublish
Résumé
The lymphatic vascular system plays a key role in cancer progression. Indeed, the activation of lymphatic endothelial cells (LECs) through the lymphangiogenic process allows for the formation of new lymphatic vessels (LVs) that represent the major route for the dissemination of solid tumors. This process is governed by a plethora of cancer-derived and microevironmental mediators that strictly activate and control specific molecular pathways in LECs. In this work we used an in vitro model of LEC activation to trigger lymphangiogenesis using a mix of recombinant pro-lymphangiogenic factors (VFS) and a co-culture system with human melanoma cells. Both systems efficiently activated LECs, and under these experimental conditions, RNA sequencing was exploited to unveil the transcriptional profile of activated LECs. Our data demonstrate that both recombinant and tumor cell-mediated activation trigger significant molecular pathways associated with endothelial activation, morphogenesis, and cytokine-mediated signaling. In addition, this system provides information on new genes to be further investigated in the lymphangiogenesis process and open the possibility for further exploitation in other tumor contexts where lymphatic dissemination plays a relevant role.
Identifiants
pubmed: 38068914
pii: ijms242316587
doi: 10.3390/ijms242316587
pmc: PMC10706153
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Association for Cancer Research
ID : AIRC IG 2019 - ID.23151
Références
J Clin Invest. 2014 Mar;124(3):922-8
pubmed: 24590277
J Clin Invest. 2011 May;121(5):2000-12
pubmed: 21540548
Cancer Res. 2009 Jan 1;69(1):349-57
pubmed: 19118020
Anticancer Res. 2016 Sep;36(9):4427-35
pubmed: 27630278
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2665-74
pubmed: 22949700
Cell Rep. 2012 Mar 29;1(3):191-9
pubmed: 22832193
Curr Opin Immunol. 2018 Aug;53:180-186
pubmed: 29879585
Microsc Res Tech. 2001 Oct 15;55(2):92-9
pubmed: 11596154
Exp Hematol Oncol. 2022 Nov 1;11(1):84
pubmed: 36320051
Oncogene. 2012 Oct 18;31(42):4499-508
pubmed: 22179834
J Med Imaging Radiat Sci. 2019 Sep;50(3):460-469.e1
pubmed: 31204313
Adv Drug Deliv Rev. 2019 Apr;144:16-34
pubmed: 31461662
Ann N Y Acad Sci. 2008;1131:235-41
pubmed: 18519976
Gastroenterology. 2015 Jun;148(7):1438-51.e8
pubmed: 25754161
Med Res Rev. 2022 Jan;42(1):576-614
pubmed: 34486138
J Cell Physiol. 2008 Aug;216(2):347-54
pubmed: 18481261
Adv Drug Deliv Rev. 2001 Aug 23;50(1-2):3-20
pubmed: 11489331
Genes Cancer. 2011 Dec;2(12):1146-58
pubmed: 22866206
Angiogenesis. 2023 Aug;26(3):313-347
pubmed: 37060495
Nat Rev Cancer. 2014 Mar;14(3):159-72
pubmed: 24561443
Cell Rep. 2018 Dec 26;25(13):3554-3563.e4
pubmed: 30590031
J Clin Invest. 2014 Mar;124(3):878-87
pubmed: 24590272